John David Chetwood

John David Chetwood

Auto-generated profile, based on publicly available information

John David Chetwood

Department of Gastroenterology, Concord Hospital, NSW, Australia; Department of Gastroenterology, St Vincent's Hospital Sydney, NSW, Australia; Department of Gastroenterology, Northern Beaches Hospital, NSW, Australia; University of Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2015 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
JCJohn D Chetwood
John D Chetwood
NLNimzing G Ladep
Nimzing G Ladep
STSimon David Taylor-Robinson
Simon David Taylor-Robinson
International partnerships in research are receiving ever greater attention, given that technology has diminished the restriction of geographical barriers with the effects of globalisation becoming more evident, and populations increasingly more mobile. In this article, we examine the merits and risks of such collaboration even when strict universal ethical guidelines are maintained. There has been widespread examples of outcomes beneficial and detrimental for both high and low –income countries which are often initially unintended. The authors feel that extreme care and forethought should be exercised by all involved parties, despite the fact that many implications from such international work can be extremely hard to predict. However ultimately the benefits gained by enhancing medical research and philanthropy are too extensive to be ignored.

24 April 2024 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
JCJohn David Chetwood
John David Chetwood
Yvonne TranYvonne Tran
Yvonne Tran
SSSreedhar Subramanian
Sreedhar Subramanian
PSPhilip J Smith
Philip J Smith
MIMarisa Iborra
Marisa Iborra
RLRupert Leong
Rupert Leong
Subcutaneous [SC] infliximab may provide multiple benefits over intravenous [IV] formulations. However, studies for efficacy and safety in inflammatory bowel disease [IBD] have been constrained by small sizes that limit the interpretation of outcomes, particularly for subgroups potentially at high risk of disease relapse. We conducted a systematic review and random-effects meta-analysis up to January 2023, to evaluate the change in clinical remission after transitioning from IV to SC infliximab in patients with IBD in clinical remission. The primary outcome was measured using the relative risk for meta-analysis. We identified 15 studies of patients established ≥ 3 months on IV infliximab, consisting of 1371 patients and 840 patient-years of follow-up. There was no loss of clinical remission in the IBD cohort overall, Crohn’s disease [CD], or perianal CD [p = 0.55 and p = 0.11 at 9–12 months, and p = 0.50 at 6 months, respectively]. Neither prior IV dose [≤ 10 mg/kg 6-weekly] [p = 0.48] nor IBD disease subtype was associated with an increased clinical relapse rate at 6 months (p = 0.48 and p = 0.45 [UC vs CD], respectively). Changing patients established on IV infliximab to an SC formulation is associated with a high ongoing clinical remission and a low adverse event rate. Furthermore, there are no signals for adverse outcomes among different IBD disease subtypes, nor in those on escalated IV infliximab dosing schedules up to 10 mg/kg 6-weekly. These data should provide patients and clinicians alike with confidence in SC infliximab use in IBD.

31 October 2018 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
JCJohn David Chetwood
John David Chetwood
PGPriya Garg
Priya Garg
PFPeter Finch
Peter Finch
MGMelita Gordon
Melita Gordon
Esophageal carcinoma causes over 380 000 deaths per year, ranking sixth worldwide in mortality amongst all malignancies. Globally, the squamous cell subtype is most common and accounts for 80% of esophageal cancers. Nonetheless, esophageal squamous cell carcinoma is much more poorly understood than esophageal adenocarcinoma, including what is driving such high prevalences, why it often presents in young patients, and shows such marked geographical delineations Areas covered: The current literature was searched for articles focusing on aetiopathogenesis of squamous cell esophageal carcinoma via a systematic review, particularly in low-resource settings. This was supplemented by papers of interest known to the authors. Expert commentary: Current putative mechanisms include polycyclic aromatic hydrocarbons, nitrosamines, acetaldehyde, cyclo-oxygenase-2 pathways, androgen and their receptor levels, as well as smoking & alcohol, micronutrient deficiencies and diet, mycotoxins, thermal damage, oral hygiene and microbiotal factors, inhaled smoke, viral infections such as HPV, and chronic irritative states. Etiology is likely multifactorial and varies geographically. Though smoking and alcohol play a predominant role in high-income settings, there is strong evidence that mycotoxins, diet and temperature effects may play an under-recognized role in low and middle-income settings.

10 July 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
JCJohn David Chetwood
John David Chetwood
AAArteen Arzivian
Arteen Arzivian
YTYvonne Tran
Yvonne Tran
SPSudarshan Paramsothy
Sudarshan Paramsothy
RLRupert W. Leong
Rupert W. Leong
Background: Subcutaneous infliximab may provide multiple benefits over intravenous formulations. However, there is uncertainty about the relative efficacy in inflammatory bowel disease (IBD).Aim: To evaluate the relative efficacy of intravenous versus subcutaneous infliximab in patients with IBD using clinical response, clinical remission, and endoscopic remission outcomes at 30‐ and 54‐week outcomes.Methods: We conducted a systematic review and network meta‐analysis with results up to August 2024. We calculated comparative efficacy using surface under the cumulative ranking curve (SUCRA), posterior probability, and contrast plots.Results: A total of 9 studies with 2519 patients met the selection criteria for inclusion; 33.6% (846/2519) of patients had Crohn's disease and 66.4% (1673/2519) had ulcerative colitis. Via SUCRA analysis, subcutaneous infliximab was ranked first in all comparisons. Via posterior probability modelling, there was strong or very strong evidence of superiority with subcutaneous over intravenous infliximab for clinical response (30‐week outcomes), clinical remission (30‐ and 54‐week outcomes), although with moderate evidence for clinical response at 54 weeks, and no evidence of any difference for endoscopic remission (54 weeks). Via contrast plot analysis, no comparison reached statistical significance.Conclusion: Subcutaneous infliximab is associated with high efficacy rates in IBD. Subcutaneous infliximab may offer clinical benefit above the intravenous formulation. This should provide patients and clinicians with confidence in using subcutaneous infliximab in IBD. Further head‐to‐head trials are needed to confirm the relative efficacy between these formulations.

10 October 2024 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
RLRupert Leong
Rupert Leong
ASAnthony Sakiris
Anthony Sakiris
AAArteen Arzivian
Arteen Arzivian
JCJohn David Chetwood
John David Chetwood
TCTHANABOON CHAEMSUPAPHAN
THANABOON CHAEMSUPAPHAN
FGFor the Australian IBD Consensus Working Group
For the Australian IBD Consensus Working Group
Background: Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential.Aims: To create a comprehensive set of statements on assessment procedures and vaccinations before starting monoclonal antibodies, Janus kinase (JAK) inhibitors or sphingosine‐1‐phosphate (S1P) modulators for IBD.Methods: We examined literature, guidelines and drug product information regarding vaccination and assessment recommendations for initiating advanced IBD therapies. Using a modified Delphi approach, delegates voted anonymously on the acceptability of these statements prior to and following consensus discussion.Results: We developed eight statements on the domains of infectious diseases screening, vaccinations and assessments prior to commencing JAK inhibitors and S1P modulators. Six statements received agreement. Pre‐advanced therapy screening for infectious diseases was established, and the vaccination protocol was revised. Malignancy, cardiovascular and thromboembolic risk assessments are necessary before initiating JAK inhibitors. Those starting S1P modulators need cardiac and ophthalmic assessments.Conclusions: These consensus statements combine vaccination and assessments on the currently available advanced therapies for IBD as a single comprehensive document that may reduce IBD complications associated with use of advanced therapies. Knowledge gaps identified during the consensus process will provide further research opportunities.

26 January 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JCJohn David Chetwood
John David Chetwood
YKYanna Ko
Yanna Ko
APAviv Pudipeddi
Aviv Pudipeddi
VKViraj Kariyawasam
Viraj Kariyawasam
SPSudarshan Paramsothy
Sudarshan Paramsothy
RLRupert Leong
Rupert Leong
INTRODUCTION: Comparative effectiveness research provides data on the relative benefits and risks between treatments. In Crohn's disease (CD), however, there are few head-to-head studies comparing advanced therapies and none with long-term follow-up. Real-world effectiveness, defined by treatment persistence, obtained from prospective population-based patient cohorts, may help determine the best sequencing and positioning of biological agents. METHODS: We analyzed the prospectively collected population-based Australian national Pharmaceutical Benefits Scheme dispensing data registry (2005–2019) for CD. There is no mandated biological agent prescribing order, and all citizens and permanent residents are eligible for treatment irrespective of insurance status. Propensity score matching was performed to reduce selection bias. RESULTS: There were 2,029 lines of therapy in 1,446 patients (median age 43 years, interquartile range 34–58, 44% male patients) over the 15-year period with 5,618 patient-years of follow-up. Per line of therapy, 915/2,029 (45.1%) patients used adalimumab, 722/2,029 (35.6%) used infliximab, 155/2,029 (7.6%) used vedolizumab, and 237/2,029 (11.7%) used ustekinumab. When used in biological agent–naive patients, there was no difference in persistence between any agent (P > 0.05). Used after first line in biological agent–experienced CD, ustekinumab had significantly better persistence than non-ustekinumab biological agents (P = 0.0018), vs anti–tumor necrosis factor (TNF) alpha therapy (P = 0.006) or vedolizumab (P < 0.001). Ustekinumab persistence was unaffected by prior biological agent exposure (P = 0.51). After anti-TNF use, ustekinumab had superior persistence to an alternative anti-TNF agent (P = 0.033) and to vedolizumab (P = 0.026). Using a propensity score–matched analysis adjusted for age, immunomodulator use, and bio-exposed status, ustekinumab had superior persistence to anti-TNF (P = 0.01). Multivariate predictors of worse persistence were the use of a non-ustekinumab biological agent (adjusted hazard ratio 2.10, P < 0.001), and bio-experienced status (adjusted hazard ratio 1.23, P < 0.001). DISCUSSION: This large national prospective database with nonhierarchical prescribing of biological agents did not identify superior persistence of any agent in bio-naive CD. However, for patients with bio-experienced CD, persistence was greater with ustekinumab.